Cargando…
A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are com...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813654/ https://www.ncbi.nlm.nih.gov/pubmed/31681618 http://dx.doi.org/10.3389/fonc.2019.01094 |
_version_ | 1783462884200677376 |
---|---|
author | Liu, Yixin Zhang, Zheyang Li, Tianhao Li, Xin Zhang, Sainan Li, Ying Zhao, Wenyuan Gu, Yunyan Guo, Zheng Qi, Lishuang |
author_facet | Liu, Yixin Zhang, Zheyang Li, Tianhao Li, Xin Zhang, Sainan Li, Ying Zhao, Wenyuan Gu, Yunyan Guo, Zheng Qi, Lishuang |
author_sort | Liu, Yixin |
collection | PubMed |
description | Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are commonly based on risk scores summarized from gene expression, are unsuitable for clinical application because of their high sensitivity to experimental batch effects and quality uncertainties of clinical samples. Using 226 samples of HGS-OvCa patients receiving platinum-taxane ACT in TCGA, we developed a qualitative transcriptional signature, consisting of four gene pairs whose within-samples relative expression orderings could robustly predict patient recurrence-free survival (RFS). In two independent test datasets, the predicted non-responders had significantly shorter RFS than the predicted responders (log-rank p < 0.05). In a test dataset containing data for patient pathological response state, the signature reclassified 12 out of 22 pathological complete response patients as non-responders and two out of 16 pathological non-complete response patients as responders. Notably, the 12 predicted non-responders in the pathological complete response group had significantly shorter RFS than the predicted responders (log-rank p = 0.0122). This qualitative transcriptional signature, which is insensitive to experimental batch effects and quality uncertainties of clinical samples, can individually identify HGS-OvCa patients who are more likely to benefit from platinum-taxane adjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-6813654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68136542019-11-01 A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy Liu, Yixin Zhang, Zheyang Li, Tianhao Li, Xin Zhang, Sainan Li, Ying Zhao, Wenyuan Gu, Yunyan Guo, Zheng Qi, Lishuang Front Oncol Oncology Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are commonly based on risk scores summarized from gene expression, are unsuitable for clinical application because of their high sensitivity to experimental batch effects and quality uncertainties of clinical samples. Using 226 samples of HGS-OvCa patients receiving platinum-taxane ACT in TCGA, we developed a qualitative transcriptional signature, consisting of four gene pairs whose within-samples relative expression orderings could robustly predict patient recurrence-free survival (RFS). In two independent test datasets, the predicted non-responders had significantly shorter RFS than the predicted responders (log-rank p < 0.05). In a test dataset containing data for patient pathological response state, the signature reclassified 12 out of 22 pathological complete response patients as non-responders and two out of 16 pathological non-complete response patients as responders. Notably, the 12 predicted non-responders in the pathological complete response group had significantly shorter RFS than the predicted responders (log-rank p = 0.0122). This qualitative transcriptional signature, which is insensitive to experimental batch effects and quality uncertainties of clinical samples, can individually identify HGS-OvCa patients who are more likely to benefit from platinum-taxane adjuvant chemotherapy. Frontiers Media S.A. 2019-10-18 /pmc/articles/PMC6813654/ /pubmed/31681618 http://dx.doi.org/10.3389/fonc.2019.01094 Text en Copyright © 2019 Liu, Zhang, Li, Li, Zhang, Li, Zhao, Gu, Guo and Qi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Yixin Zhang, Zheyang Li, Tianhao Li, Xin Zhang, Sainan Li, Ying Zhao, Wenyuan Gu, Yunyan Guo, Zheng Qi, Lishuang A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title | A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title_full | A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title_fullStr | A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title_full_unstemmed | A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title_short | A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy |
title_sort | qualitative transcriptional signature for predicting recurrence risk for high-grade serous ovarian cancer patients treated with platinum-taxane adjuvant chemotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813654/ https://www.ncbi.nlm.nih.gov/pubmed/31681618 http://dx.doi.org/10.3389/fonc.2019.01094 |
work_keys_str_mv | AT liuyixin aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhangzheyang aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT litianhao aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT lixin aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhangsainan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT liying aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhaowenyuan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT guyunyan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT guozheng aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT qilishuang aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT liuyixin qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhangzheyang qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT litianhao qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT lixin qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhangsainan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT liying qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT zhaowenyuan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT guyunyan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT guozheng qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy AT qilishuang qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy |